ERBB2 and breast cancer: In particular, pre-NCT miR-222 upregulation, post-NCT miR-20a upregulation, and miR-451 downregulation are strongly associated with unresponsiveness to NCT in HR+/HER2- BC patients (AUC: 0.80, 0.79, and 0.71).